November 2005
Worldwide Biotech;Nov2005, Vol. 17 Issue 11, p4
Trade Publication
No abstract available.


Related Articles

  • Deals Roundup.  // BioWorld Today;1/15/2008, Vol. 19 Issue 10, p5 

    The article reports on a nonexclusive license deal signed by Crucell NV, granting ISU Abxis rights to its STAR research technology. The agreement covers both a research evaluation of STAR for the production of recombinant proteins and an option for a commercial license. Financial terms of the...

  • Collaborations: DSM Biologics and Crucell Announce Licensing Deal with LFB Biotechnologies.  // Pharmaceutical Technology;Sep2007, Vol. 31 Issue 9, p134 

    The article reports that DSM Biologics of New Jersey and the biotechnology company Crucell NV of the Netherlands has signed a nonexclusive research licensing agreement with LFB Biotechnologies of Paris, France. It is stated that the LFB will use the PER.C6 production technology of Crucell to...

  • OTHER NEWS TO NOTE.  // BioWorld Today;4/9/2008, Vol. 19 Issue 69, p6 

    This section offers news briefs related to the biotechnology industries. Full global rights to the I-3D portfolio of orally active, dihydroorotate dehydrogenase inhibiting compounds for the treatment of autoimmune diseases and transplant rejection have been acquired by Chelsea Therapeutics...

  • CRUCELL/MERIAL SIGN LICENSE PACT FOR PER.C6 TECHNOLOGY.  // Worldwide Biotech;Dec2004, Vol. 16 Issue 12, p6 

    Reports on a license agreement entered into by Dutch biotechnology firm Crucell N.V. with Merial, an animal health company. Technology developed by Crucell to be utilized by Merial under the agreement; Overview of the terms of the agreement; Remarks from Robert Nordgren, head of Biologics...

  • Crucell Signs Sanofi in $113M Rabies Deal.  // Bioworld Week;1/7/2008, Vol. 16 Issue 1, p4 

    The article reports on the $113 million deal between Crucell NV and vaccine maker Sanofi Pasteur Inc. Crucell's development of rabies monoclonal antibodies will be used in conjunction with Sanofi's rabies vaccine. The article cites that the deal entitles Crucell to an undisclosed royalty...

  • DSM Biologics and Crucell Enter Licensing Deal. Bryner, Michelle // Chemical Week;8/1/2007, Vol. 169 Issue 26, p19 

    The article reports that DSM Biologics and Crucell of Leiden, the Netherlands have entered into an agreement to license a manufacturing technology based on the companies' jointly developed PER.C6 cell line, to LFB Biotechnologies of Paris, France. LFB will use the licensed technology to develop...

  • ProFibrix concludes licensing agreement with Crucell.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p15 

    The article reports on the decision of ProFibrix BV to establish a commercial license agreement with Crucell NV for PER.C6, a human protein production platform in Netherlands. It states that the platform permits ProFibrix to produce recombinant human fibrinogen at levels that assist the...

  • Crucell signs licensing deal. Tyler, Alan // European Chemical News;6/14/2004, Vol. 80 Issue 2104, p29 

    Reports on the research licensing deal signed by Dutch biotechnology player Crucell with PanGenetics. Significance of the deal to PanGenetics; Payment and annual maintenance fees to be received by Crucell and DSM Biologics; Description made by PanGenetics on itself.

  • MorphoSys Signs Cooperative Agreements.  // Pharmaceutical Technology;Oct2006, Vol. 30 Issue 10, p166 

    The article announces the license agreement signed by MorphoSys AG with Crucell NV and DSM Biologics. The agreement allows the former to use a cell line designed to produce clinical-grade material and develop its therapeutic human antibody program. The financial details of these agreements were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics